Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

Zinonos,Irene; Luo,Ke-Wang; Labrinidis,Agatha; Liapis,Vasilios; Hay,Shelley; Panagopoulos,Vasilios; Denichilo,Mark; Ko,Chun-Hay; Yue,Grace  Gar-Lee; Lau,Clara  Bik-San; Ingman,Wendy; Ponomarev,Vladimir; Atkins,Gerald  J.; Findlay,David  M.; Zannettino,Andrew C.W.; Evdokiou,Andreas

doi:10.3892/ijo.2014.2468

August-2014 Volume 45 Issue 2

Full Size Image

Cover Legend PDF

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2014 Volume 45 Issue 2

Full Size Image

Cover Legend PDF

Article Open Access

Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

Authors:
- Irene Zinonos
- Ke-Wang Luo
- Agatha Labrinidis
- Vasilios Liapis
- Shelley Hay
- Vasilios Panagopoulos
- Mark Denichilo
- Chun-Hay Ko
- Grace Gar-Lee Yue
- Clara Bik-San Lau
- Wendy Ingman
- Vladimir Ponomarev
- Gerald J. Atkins
- David M. Findlay
- Andrew C.W. Zannettino
- Andreas Evdokiou
View Affiliations / Copyright

Affiliations: Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute and Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, Australia, Institute of Chinese Medicine and State Key Laboratory of Phytochemistry and Plant Resources in West China, The Chinese University of Hong Kong, Hong Kong, P.R. China, School of Medicine at the Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville and the Robinson Institute, University of Adelaide, Adelaide, Australia, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Discipline of Orthopaedics and Trauma, University of Adelaide, Adelaide, Australia, Myeloma Research Laboratory, School of Medical Sciences, Faculty of Health Science and Centre for Personalized Cancer Medicine, University of Adelaide, Adelaide, Australia

Copyright: © Zinonos et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
Pages: 532-540
|
Published online on: May 27, 2014

https://doi.org/10.3892/ijo.2014.2468
Expand metrics +

Abstract

Osteoprotegerin (OPG) is a secreted member of the TNF receptor superfamily, which binds to the receptor activator of nuclear factor κB ligand (RANKL) and inhibits osteoclast activity and bone resorption. Systemic administration of recombinant OPG was previously shown to inhibit tumor growth in bone and to prevent cancer-induced osteolysis. In this study, we examined the effect of OPG, when produced locally by breast cancer cells located within bone, using a mouse model of osteolytic breast cancer. MDA-MB-231-TXSA breast cancer cells, tagged with a luciferase reporter gene construct and engineered to overexpress full-length human OPG, were transplanted directly into the tibial marrow cavity of nude mice. Overexpression of OPG by breast cancer cells protected the bone from breast cancer-induced osteolysis and diminished intra-osseous tumor growth but had no effect on extra-skeletal tumor growth. This effect was associated with a significant reduction in the number of osteoclasts that lined the bone surface, resulting in a net increase in bone volume. Despite limiting breast cancer-mediated bone loss, OPG overexpression resulted in a significant increase in the incidence of pulmonary metastasis. Our results demonstrate that inhibition of osteoclastic bone resorption by OPG when secreted locally by tumors in bone may affect the behaviour of cancer cells within the bone microenvironment and their likelihood of spreading and establishing metastasis elsewhere in the body.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
3	Coleman RE, Lipton A, Roodman GD, et al: Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 36:615–620. 2010. View Article : Google Scholar : PubMed/NCBI
4	Coleman RE, Marshall H, Cameron D, et al: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 365:1396–1405. 2011. View Article : Google Scholar : PubMed/NCBI
5	Guise TA, Brufsky A and Coleman RE: Understanding and optimizing bone health in breast cancer. Curr Med Res Opin. 26(Suppl 3): S3–S20. 2010. View Article : Google Scholar
6	Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar
7	Tsuda E, Goto M, Mochizuki S, et al: Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 234:137–142. 1997. View Article : Google Scholar : PubMed/NCBI
8	Bucay N, Sarosi I, Dunstan CR, et al: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260–1268. 1998. View Article : Google Scholar : PubMed/NCBI
9	Buijs JT and van der Pluijm G: Osteotropic cancers: from primary tumor to bone. Cancer Lett. 273:177–193. 2009. View Article : Google Scholar : PubMed/NCBI
10	Croucher PI, Shipman CM, Lippitt J, et al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 98:3534–3540. 2001. View Article : Google Scholar : PubMed/NCBI
11	Corey E, Brown LG, Kiefer JA, et al: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 65:1710–1718. 2005. View Article : Google Scholar : PubMed/NCBI
12	Fisher JL, Thomas-Mudge RJ, Elliott J, et al: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66:3620–3628. 2006. View Article : Google Scholar
13	Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH and Corey E: Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 7:2977–2983. 2001.PubMed/NCBI
14	Chen G, Sircar K, Aprikian A, Potti A, Goltzman D and Rabbani SA: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 107:289–298. 2006. View Article : Google Scholar : PubMed/NCBI
15	Zinonos I, Labrinidis A, Lee M, et al: Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res. 26:630–643. 2011. View Article : Google Scholar : PubMed/NCBI
16	Labrinidis A, Diamond P, Martin S, et al: Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res. 15:1998–2009. 2009. View Article : Google Scholar : PubMed/NCBI
17	Endo-Munoz L, Cumming A, Rickwood D, et al: Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 70:7063–7072. 2010. View Article : Google Scholar : PubMed/NCBI
18	Luo KW, Ko CH, Yue GG, et al: Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models. Cancer Lett. 339:42–48. 2013. View Article : Google Scholar : PubMed/NCBI
19	Body JJ, Diel IJ, Bell R, et al: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 111:306–312. 2004. View Article : Google Scholar : PubMed/NCBI
20	Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 9:77–85. 2009. View Article : Google Scholar
21	Bundred NJ, Campbell ID, Davidson N, et al: Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer. 112:1001–1010. 2008. View Article : Google Scholar
22	Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J and Ashley S: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11:59–65. 1993.PubMed/NCBI
23	Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7:377–387. 2001.
24	Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles